TY - JOUR
T1 - Graft-versus-host disease
AU - Ferrara, James LM
AU - Levine, John E.
AU - Reddy, Pavan
AU - Holler, Ernst
N1 - Funding Information:
This work was supported in part by grants from the National Institutes of Health (Bethesda, MD, USA), P01 CA 39542, and the Jose Carreras Foundation. JLMF is a Doris Duke distinguished clinical scientist and an American Cancer Society clinical research professor.
PY - 2009
Y1 - 2009
N2 - Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk haematological malignant disorders and other life-threatening haematological and genetic diseases. The main complication of HCT is graft-versus-host disease (GVHD), an immunological disorder that affects many organ systems, including the gastrointestinal tract, liver, skin, and lungs. The number of patients with this complication continues to grow, and many return home from transplant centres after HCT requiring continued treatment with immunosuppressive drugs that increases their risks for serious infections and other complications. In this Seminar, we review our understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease. We also summarise supportive-care measures that are essential for management of this medically fragile population.
AB - Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk haematological malignant disorders and other life-threatening haematological and genetic diseases. The main complication of HCT is graft-versus-host disease (GVHD), an immunological disorder that affects many organ systems, including the gastrointestinal tract, liver, skin, and lungs. The number of patients with this complication continues to grow, and many return home from transplant centres after HCT requiring continued treatment with immunosuppressive drugs that increases their risks for serious infections and other complications. In this Seminar, we review our understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease. We also summarise supportive-care measures that are essential for management of this medically fragile population.
UR - http://www.scopus.com/inward/record.url?scp=65349171937&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(09)60237-3
DO - 10.1016/S0140-6736(09)60237-3
M3 - Review article
C2 - 19282026
AN - SCOPUS:65349171937
SN - 0140-6736
VL - 373
SP - 1550
EP - 1561
JO - The Lancet
JF - The Lancet
IS - 9674
ER -